Deferoxamine-induced dysplasia of the knee: sonographic features and diagnostic performance compared with magnetic resonance imaging.
OBJECTIVE
To evaluate the features and diagnostic performance of sonography in the assessment of deferoxamine-induced dysplasia of the knee.


METHODS
The left knees of 32 patients with thalassemia who were receiving regular blood transfusions and chelation therapy were studied with sonography for signs of deferoxamine-induced bone dysplasia. Abnormal physeal and metaphyseal changes detected on sonography included notching at the metaphyseal corner, a blurred or irregular peripheral juxtaphyseal metaphyseal contour, and widening of the peripheral juxtaphyseal metaphyseal echogenic interface. The accuracy of sonography in diagnosing dysplasia was evaluated by using magnetic resonance imaging as the standard of reference.


RESULTS
There were 14 true-positive findings, 10 true-negative findings, 7 false-negative findings, and 1 false-positive sonographic diagnosis of dysplasia, giving 67% sensitivity, 91% specificity, a 93% positive predictive value, and a 59% negative predictive value.


CONCLUSIONS
Sonography was specific but only moderately sensitive in the diagnosis of deferoxamine-induced dysplasia at the knee when compared with magnetic resonance imaging.
Chan
Y L
YL
Department of Diagnostic Radiology and Organ Imaging, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin.
Chu
C W
CW
Chik
K W
KW
Pang
L M
LM
Shing
M K
MK
Li
C K
CK
D000293:Adolescent; D001803:Blood Transfusion; D001848:Bone Diseases, Developmental / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000473:pathology; D002614:Chelating Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D003676:Deferoxamine / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007717:Knee / Q000000981:diagnostic imaging* / Q000473:pathology; D008279:Magnetic Resonance Imaging; D008297:Male; D012680:Sensitivity and Specificity; D014463:Ultrasonography; D017086:beta-Thalassemia / Q000097:blood / Q000628:therapy*
D002614:Chelating Agents; D003676:Deferoxamine